Bronchial asthma in children. Sublingual immunotherapy treatment alternative with dermatofhagoides pteronyssinus;Asma bronquial en niños. Inmunoterapia sublingual con dermatofhagoides pteronyssinus como alternativa de tratamiento

Pediatrika

Volumn 25, Issue 6, 2005, Pages 18-21

  Rodriguez Santos O ^a,c   Rodriguez Moya V ^b  

^a UNIVERSIDAD DE CAMAGÜEY   (Cuba)

^b Policlínico Comunitario Docente La Jagua   (Cuba)

^c E/ Bembeta y Lugareño ^*  (Cuba)

Author keywords

Allergy; Bronchial asthma; Dermatophagoides pteronyssinus; Sublingual immunotherapy

Indexed keywords

BRONCHODILATING AGENT; DRUG VEHICLE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; PROPYLENE GLYCOL; STEROID;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; DERMATOPHAGOIDES PTERONYSSINUS; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; SPIROMETRY; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 23044507683     PISSN: 02113465     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Martínez B, Ayala Mejías S, Molina Quirós C, Colmenero Ruiz M, Sanz Fernández R. Inmunoterapia sublingual en la rinitis alérgica estacional. Revisión de 30 pacientes. Acta Otorrinolaringol Esp 2005; 56: 112-115.
2. Frati F, Sensi L, Di Rienzo V, Senna GE, Incorvaia C, Marcucci F. A model for management of sublingual immunotherapy. Allerg Immunol (Paris) 2003; 35(2): 56-60.
3. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111 (3):437-48.
4. Madonini E, Agostinis F, Barra R, Berra A, Donadio D, Pappacoda A, Stefani E, Tierno E. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 2003; 16(1):73-9.
5. Schmidt-Weber CB, Blaser K. T-cell tolerance in allergic response. Allergy 2002; (57):762-768.
6. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33(2): 206-10.
7. Silvestri M, Spallarossa D, Battistini E, Sabatini F, Pecora S, Parmiani S; Rossi GA. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol 2002; 12(1):52-9.
8. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990; 18(5):277-84.
9. Passalacqua G, Canonica GW. Allergen-specific sublingual immunotherapy for respiratory allergy. Bio-Drugs 2001; 15(8):509-19.
10. Bahçeciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32(1):49-55.
11. Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol 2001; 107(3):441-4.
12. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55(9):842-9.
13. Guez S, Vatrinet C, Fadel R, André C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000; 55(4):369-75.
14. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121(3):229-34.
15. Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma-a placebo controlled study. Ann Allergy Asthma Immunol 1999; 82(5):485-90.
16. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, André C. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54(3):249-60.
17. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351(9103):629-32, 1998.
18. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997; 8(1):21-7.
19. Almagro E, Asensio O, Bartolomé JM, Bosque M, de la Hoz B, Dolz I, Elorza J, Ferreiro M, García JM, Losada E. Estudio multicéntrico de farmacovigilancia de inmunoterapia sublingual en pacientes alérgicos. Allergol Immunopathol (Madr) 1995; 23(4): 153-9.
20. Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergol Immunopathol (Madr) 1994; 22(5):209-16.
21. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.